{
  "source": "PA-Notification-Mycapssa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1340-5\nProgram Prior Authorization/Notification\nMedication Mycapssa® (octreotide)\nP&T Approval Date 12/2020, 12/20021, 12/2022, 12/2023, 1/2024\nEffective Date 4/1/2025\n1. Background:\nMycapssa (octreotide) is a somatostatin analog indicated for long-term maintenance treatment in\nacromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.\n2. Coverage Criteriaa:\nA. Acromegaly\n1. Initial Authorization\na. Mycapssa will be approved based both of the following criteria:\n(1) Diagnosis of acromegaly\n-AND-\n(2) Patient has responded to and tolerated treatment with one of the following\nsomatostatin analogs:\ni. Sandostatin (octreotide) or Sandostatin LAR\nii. Somatuline Depot (lanreotide)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Mycapssa will be approved based on of the following criterion:\n(1) Documentation of positive clinical response to Mycapssa therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n• Medical Necessity may be in place.\n4. References:\n1. Mycapssa [package insert]. Scotland, UK: MW Encap Ltd.; August 2024.\nProgram Prior Authorization/Notification – Mycapssa® (octreotide)\nChange Control\n11/2020 New program\n12/2021 Annual review with no change to clinical criteria.\n12/2022 Annual review with no change to clinical criteria. Added state mandate\nf",
    " – Mycapssa® (octreotide)\nChange Control\n11/2020 New program\n12/2021 Annual review with no change to clinical criteria.\n12/2022 Annual review with no change to clinical criteria. Added state mandate\nfootnote and updated reference.\n12/2023 Annual review with no change to clinical criteria.\n1/2025 Annual review with no change to clinical criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}